A Clinical Trial to Evaluate the Effects of Super Lungs Liquid Drops on Respiratory Comfort, Airway Soothing, and Overall Well-Being

N/AActive Not RecruitingNCT07694284

SuperBonsai Inc.35 enrolled

Overview

This is a single-group, open-label, fully decentralized (virtual) clinical trial evaluating the effects of Super Lungs Liquid Drops on respiratory comfort, airway soothing, and overall well-being in generally healthy adults aged 18-65 who experience bothersome respiratory symptoms. All 35 enrolled participants will receive the active study product and self-administer 2 mL of the drops daily (two full droppers of 1 mL each, once daily with the first meal of the day) for 12 weeks.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Coughing Throat Irritation

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Adults aged 18-65 years. * Over the past two months, has experienced bothersome coughing on a weekly basis. * Anyone who has experienced issues with at least two of the following over the past four weeks: chest tightness or congestion; persistent throat irritation or itchiness; excess mucus or phlegm buildup. * Generally healthy, without any uncontrolled chronic disease. * Willing to maintain their current diet, sleep pattern, and activity levels for the duration of the trial. * Resides in the United States. * Has access to the internet and a device (smartphone, tablet, or computer) capable of completing online questionnaires. * Willing to follow the study protocol and complete all required assessments. Exclusion Criteria: * Anyone with a known allergy or sensitivity to any of the study product ingredients. * Anyone with a known allergy to plants in the Asteraceae/Compositae family. * Women who are pregnant, breastfeeding, or planning to become pregnant during the study period. * Anyone currently taking immunosuppressant medications (e.g., cyclosporine, methotrexate, biologics such as adalimumab or infliximab). * Anyone with a diagnosed autoimmune disorder (e.g., lupus, rheumatoid arthritis, multiple sclerosis). * Anyone with uncontrolled hypertension or currently taking antihypertensive medications, diuretics, or corticosteroids. * Anyone currently taking anticoagulant or antiplatelet medications (e.g., warfarin, heparin, clopidogrel). * Anyone with a chronic health condition that could impact their participation in this study, such as cancer, mental health disorders, a history of serious illness in the last three months, a history of substance abuse, or planned surgery during the study period. * Anyone with a history of alcohol use disorder or currently in alcohol recovery. * Anyone currently participating in another research study or who plans to participate in another study during the study period. (

Outcomes

Primary Outcomes

Respiratory comfort

Change in self-reported respiratory comfort assessed by questionnaires.

Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12

Normal airway function

Change in self-reported normal airway function assessed by questionnaires.